![Cara Weyker](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Perfil
Cara Weyker worked as a Vice President-Regulatory Quality & Compliance at Horizon Pharma, Inc. She completed her undergraduate degree from Ripon College in 1985 and earned an MBA from Keller Graduate School of Management in 1992.
Antiguos cargos conocidos de Cara Weyker.
Empresas | Cargo | Fin |
---|---|---|
Horizon Pharma, Inc.
![]() Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL. | Oficial de Cumplimiento | - |
Formación de Cara Weyker.
Ripon College | Undergraduate Degree |
Keller Graduate School of Management | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Horizon Pharma, Inc.
![]() Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL. | Health Technology |
- Bolsa de valores
- Insiders
- Cara Weyker